Main menu

Webinar: rAAV genome sequencing uncovers transgene integrity and packaging impurities

  • Published on: May 13 2024

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar highlighted how nanopore sequencing was evaluated as a comprehensive and sensitive QC method for rAAVs, supporting internal research activities at AstraZeneca.

During this webinar, viewers learnt:

  • Raw material validation through whole plasmid sequencing

  • ITR-ITR sequencing of whole AAV genomes and truncation hotspot detection

  • Contamination detection in bioreactor batches through sequencing of residual DNA

Authors: Daniel Jachimowicz, Senior Bioscience Scientist and Bastian Schiffthaler, Senior Data Scientist from AstraZeneca BioPharmaceuticals R&D, Sweden.

Getting started

Buy a MinION starter pack Nanopore store Sequencing service providers Channel partners

Quick links

Intellectual property Cookie policy Corporate reporting Privacy policy Terms, conditions and policies Accessibility

About Oxford Nanopore

Contact us News Media resources & contacts Investor centre Careers BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Spanish flag